Total Payments
$17,535
2024 Payments
$1,835
Companies
52
Transactions
550
Medicare Patients
6,628
Medicare Billing
$1.7M
Payment Breakdown by Category
Food & Beverage$17,425 (99.4%)
Other$107.57 (0.6%)
Education$2.85 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $17,425 | 547 | 99.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $107.57 | 1 | 0.6% |
| Education | $2.85 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Daiichi Sankyo Inc. | $2,124 | 127 | $0 (2019) |
| ABBVIE INC. | $1,611 | 38 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $1,588 | 32 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,452 | 12 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $1,039 | 9 | $0 (2020) |
| Amgen Inc. | $818.48 | 14 | $0 (2023) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $773.04 | 38 | $0 (2024) |
| PFIZER INC. | $765.43 | 38 | $0 (2024) |
| Egalet US Inc | $620.24 | 56 | $0 (2018) |
| Lilly USA, LLC | $522.47 | 16 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,835 | 33 | AstraZeneca Pharmaceuticals LP ($503.64) |
| 2023 | $1,363 | 40 | ABBVIE INC. ($356.43) |
| 2022 | $1,413 | 48 | ABBVIE INC. ($278.65) |
| 2021 | $1,491 | 46 | AbbVie Inc. ($301.27) |
| 2020 | $1,390 | 47 | Allergan, Inc. ($183.68) |
| 2019 | $3,003 | 73 | Daiichi Sankyo Inc. ($418.34) |
| 2018 | $2,918 | 97 | Daiichi Sankyo Inc. ($1,086) |
| 2017 | $4,122 | 166 | Daiichi Sankyo Inc. ($619.52) |
All Payment Transactions
550 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/14/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Respiratory | ||||||
| 11/01/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $14.45 | General |
| Category: NEUROSCIENCE | ||||||
| 10/31/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $20.59 | General |
| Category: Gastroenterology | ||||||
| 10/23/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $21.45 | General |
| Category: NEUROSCIENCE | ||||||
| 10/02/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $123.44 | General |
| Category: Central Nervous System | ||||||
| 09/26/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: NEUROSCIENCE | ||||||
| 09/17/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $22.02 | General |
| Category: Gastroenterology | ||||||
| 09/11/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $22.44 | General |
| Category: Gastroenterology | ||||||
| 09/11/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $9.85 | General |
| Category: Gastroenterology | ||||||
| 08/20/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $32.69 | General |
| Category: NEUROSCIENCE | ||||||
| 08/05/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $27.86 | General |
| Category: PAIN | ||||||
| 06/11/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $21.14 | General |
| Category: Gastroenterology | ||||||
| 06/06/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $23.49 | General |
| Category: Gastroenterology | ||||||
| 06/06/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $20.27 | General |
| Category: Gastroenterology | ||||||
| 06/05/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $128.16 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/04/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 06/03/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $24.21 | General |
| Category: PAIN | ||||||
| 05/23/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $8.76 | General |
| Category: NEUROSCIENCE | ||||||
| 05/21/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $126.83 | General |
| Category: Respiratory | ||||||
| 05/14/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $33.08 | General |
| Category: NEUROSCIENCE | ||||||
| 05/13/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $24.80 | General |
| Category: Gastroenterology | ||||||
| 05/07/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $12.80 | General |
| Category: Gastroenterology | ||||||
| 05/07/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $5.34 | General |
| Category: Gastroenterology | ||||||
| 03/19/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: RESPIRATORY | ||||||
| 03/14/2024 | AstraZeneca Pharmaceuticals LP | ANDEXXA (Biological) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Rare Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 1,543 | 5,576 | $1.4M | $393,618 |
| 2022 | 17 | 1,597 | 5,412 | $1.5M | $396,905 |
| 2021 | 21 | 1,740 | 5,880 | $1.7M | $478,851 |
| 2020 | 23 | 1,748 | 7,075 | $1.7M | $393,996 |
Total Patients
6,628
Total Services
23,943
Medicare Billing
$1.7M
Procedure Codes
78
All Medicare Procedures & Services
78 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 349 | 2,795 | $559,000 | $206,392 | 36.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 98 | 947 | $142,050 | $62,701 | 44.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 253 | 519 | $155,700 | $54,241 | 34.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 99 | 140 | $42,000 | $15,124 | 36.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 99 | 99 | $44,550 | $12,985 | 29.1% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2023 | 332 | 695 | $229,350 | $8,583 | 3.7% |
| 64493 | Injection of lower or sacral spine facet joint using imaging guidance, single level | Facility | 2023 | 40 | 49 | $39,200 | $5,589 | 14.3% |
| 64483 | Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | Facility | 2023 | 41 | 46 | $46,000 | $5,480 | 11.9% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 51 | 78 | $31,200 | $4,790 | 15.4% |
| 64635 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | Facility | 2023 | 14 | 16 | $24,000 | $3,811 | 15.9% |
| 62323 | Injection of substance into lower spine canal using imaging guidance | Facility | 2023 | 42 | 44 | $44,000 | $3,557 | 8.1% |
| 64494 | Injection of lower or sacral spine facet joint using imaging guidance, second level | Facility | 2023 | 40 | 49 | $19,600 | $3,131 | 16.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 17 | 17 | $5,650 | $2,265 | 40.1% |
| 64405 | Injection of anesthetic agent and/or steroid into upper neck and back of head nerve | Office | 2023 | 14 | 18 | $13,200 | $1,512 | 11.5% |
| 20553 | Injection of trigger points, 3 or more muscles | Office | 2023 | 23 | 29 | $5,100 | $1,481 | 29.0% |
| 64636 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | Facility | 2023 | 14 | 17 | $12,750 | $1,203 | 9.4% |
| 64484 | Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | Facility | 2023 | 17 | 18 | $9,000 | $772.20 | 8.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 339 | 2,639 | $527,800 | $205,363 | 38.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 314 | 716 | $214,800 | $68,105 | 31.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 84 | 813 | $121,950 | $48,793 | 40.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 85 | 113 | $33,900 | $12,833 | 37.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 92 | 92 | $41,400 | $12,612 | 30.5% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2022 | 315 | 590 | $194,700 | $7,337 | 3.8% |
| 64635 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | Facility | 2022 | 28 | 28 | $42,000 | $6,720 | 16.0% |
| 64493 | Injection of lower or sacral spine facet joint using imaging guidance, single level | Facility | 2022 | 47 | 57 | $45,600 | $6,618 | 14.5% |
About Dr. Devinder Kumar, MD
Dr. Devinder Kumar, MD is a Pain Medicine healthcare provider based in Santa Clarita, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/01/2005. The National Provider Identifier (NPI) number assigned to this provider is 1548251390.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Devinder Kumar, MD has received a total of $17,535 in payments from pharmaceutical and medical device companies, with $1,835 received in 2024. These payments were reported across 550 transactions from 52 companies. The most common payment nature is "Food and Beverage" ($17,425).
As a Medicare-enrolled provider, Kumar has provided services to 6,628 Medicare beneficiaries, totaling 23,943 services with total Medicare billing of $1.7M. Data is available for 4 years (2020–2023), covering 78 distinct procedure/service records.
Ad
Practice Information
- Specialty Pain Medicine
- Location Santa Clarita, CA
- Active Since 11/01/2005
- Last Updated 07/30/2022
- Taxonomy Code 207LP2900X
- Entity Type Individual
- NPI Number 1548251390
Products in Payments
- Morphabond ER (Drug) $1,626
- UBRELVY (Drug) $762.37
- QULIPTA (Drug) $735.12
- RELISTOR (Drug) $673.01
- NURTEC ODT (Drug) $597.01
- ARYMO ER (Drug) $595.47
- Aimovig (Biological) $581.40
- Movantik (Drug) $570.88
- INVOKANA (Drug) $563.72
- XARELTO (Drug) $475.00
- AJOVY (Biological) $441.02
- LYRICA (Drug) $391.38
- AIRSUPRA (Drug) $378.65
- FARXIGA (Drug) $374.98
- Tymlos (Biological) $348.99
- DUEXIS (Drug) $327.21
- Nucynta (Drug) $306.56
- AJOVY (Drug) $303.56
- Trudhesa (Drug) $289.55
- Xtampza ER (Drug) $282.28
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.